Advanced Biomed Inc Other Executive Compensation Disclosures
Every other executive-compensation XBRL fact the company filed (policies, award timing, footnotes, adjustments), newest first. Long text is shortened; the filing has the full text.
- 2026-06-04: Disclosure Err Compensation Analysis; Qualifiers RestatementDate: 2025-06-30; Period 2024-07-01..2025-06-30; Value We have adopted an executive incentive compensation recovery policy pursuant to Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act (“Rule 10D-1”), and Listing Rule 5608 adopted by Nasdaq (the “Listing Standards”) to provide for the recovery of certain incentive-based comp….
- 2026-06-04: Disclosure Insider Trading Policies Proc Adopted; Period 2024-07-01..2025-06-30; Value Yes.
- 2026-05-15: Disclosure Non Rule10b51Arr Adopted; Period 2026-01-01..2026-03-31; Value No.
- 2026-05-15: Disclosure Rule10b51Arr Adopted; Period 2026-01-01..2026-03-31; Value No.
| Filed | Disclosure | Qualifiers | Period | Value |
|---|---|---|---|---|
| 2026-06-04 DEF 14A | Err Compensation Analysis | RestatementDate: 2025-06-30 | 2024-07-01..2025-06-30 | We have adopted an executive incentive compensation recovery policy pursuant to Section 10D of the Exchange Act, Rule 10D-1 promulgated under the Exchange Act (“Rule 10D-1”), and Listing Rule 5608 adopted by Nasdaq (the “Listing Standards”) to provide for the recovery of certain incentive-based comp… |
| 2026-06-04 DEF 14A | Insider Trading Policies Proc Adopted | 2024-07-01..2025-06-30 | Yes | |
| 2026-05-15 10-Q | Non Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Rule10b51Arr Adopted | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Non Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-05-15 10-Q | Rule10b51Arr Terminated | 2026-01-01..2026-03-31 | No | |
| 2026-02-13 10-Q | Non Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-13 10-Q | Rule10b51Arr Adopted | 2025-10-01..2025-12-31 | No | |
| 2026-02-13 10-Q | Non Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2026-02-13 10-Q | Rule10b51Arr Terminated | 2025-10-01..2025-12-31 | No | |
| 2025-11-19 10-Q | Non Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-19 10-Q | Rule10b51Arr Adopted | 2025-07-01..2025-09-30 | No | |
| 2025-11-19 10-Q | Non Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-11-19 10-Q | Rule10b51Arr Terminated | 2025-07-01..2025-09-30 | No | |
| 2025-10-08 10-K | Non Rule10b51Arr Terminated | 2024-07-01..2025-06-30 | No | |
| 2025-10-08 10-K | Rule10b51Arr Terminated | 2024-07-01..2025-06-30 | No | |
| 2025-10-08 10-K | Non Rule10b51Arr Adopted | 2024-07-01..2025-06-30 | No | |
| 2025-10-08 10-K | Rule10b51Arr Adopted | 2024-07-01..2025-06-30 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Terminated | 2025-01-01..2025-03-31 | No | |
| 2025-05-15 10-Q | Non Rule10b51Arr Adopted | 2025-01-01..2025-03-31 | No | |
| 2025-04-15 10-Q | Rule10b51Arr Terminated | 2024-07-01..2024-12-31 | No | |
| 2025-04-15 10-Q | Rule10b51Arr Adopted | 2024-07-01..2024-12-31 | No | |
| 2025-04-15 10-Q | Non Rule10b51Arr Terminated | 2024-07-01..2024-12-31 | No | |
| 2025-04-15 10-Q | Non Rule10b51Arr Adopted | 2024-07-01..2024-12-31 | No |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |